Abstract
The safety of high-dose oseltamivir during treatment of 2009 H1N1 influenza A infection for critically ill patients is unknown. Here we report on a case patient with severe, delayed-onset neuropsychiatric symptoms after administration of high-dose oseltamivir. Clinicians should be vigilant to the possible increased risk of complications associated with high-dose oseltamivir therapy for 2009 H1N1 influenza A infection.
Publication types
-
Case Reports
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antiviral Agents / administration & dosage
-
Antiviral Agents / adverse effects*
-
Antiviral Agents / blood
-
Confusion / chemically induced
-
Hallucinations / chemically induced
-
Humans
-
Influenza A Virus, H1N1 Subtype*
-
Influenza, Human / complications
-
Influenza, Human / drug therapy*
-
Influenza, Human / virology
-
Leukemia, Promyelocytic, Acute / complications
-
Leukemia, Promyelocytic, Acute / therapy
-
Male
-
Neurotoxicity Syndromes / etiology*
-
Oseltamivir / administration & dosage
-
Oseltamivir / adverse effects*
-
Oseltamivir / blood
-
Transplantation, Autologous
Substances
-
Antiviral Agents
-
Oseltamivir